USE OF AGENTS FOR INDUCING SPECIFIC IMMUNITY AGAINST SARS-COV-2 IN Children
The group of inventions relates to biotechnology, immunology and virology. Described is the use of an agent containing an expression vector based on human adenovirus serotype 26 or human adenovirus serotype 5 in which the 1 and 3 sites are deleted, having an integrated expression cassette selected f...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The group of inventions relates to biotechnology, immunology and virology. Described is the use of an agent containing an expression vector based on human adenovirus serotype 26 or human adenovirus serotype 5 in which the 1 and 3 sites are deleted, having an integrated expression cassette selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, the present invention relates to a simian adenovirus expression vector based on a simian adenovirus serotype 25 in which 1 and 3 sites are deleted, said expression vector having an integrated expression cassette selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3, or containing only component 2.
这组发明涉及生物技术、免疫学和病毒学。描述了一种含有表达载体的药剂在1月龄或更大龄的儿童中诱导针对严重急性呼吸综合征病毒SARS-COV-2的特异性免疫的用途,所述表达载体基于人腺病毒血清型26或人腺病毒血清型5,其中Е1和Е3位点缺失,所述表达载体具有选自SEQ ID NO:1、SEQ ID NO:2、SEQ ID NO:3的整合表达盒,或者基于猿猴腺病毒血清型25,其中Е1和Е3位点缺失,所述表达载体具有选自SEQ ID NO:4、SEQ ID NO:2、SEQ ID NO:3的整合表达盒,或者仅含有成分2。 |
---|